Tumor biomarker analysis of the group’s orthotopic model treated with combined therapy suggested that mirdametinib blocked feedback induction of the PI3K pathway’s effector activity on Ras-Raf-MEK while also suppressing the activity of the PI3K downstream target protein S6 (pS6), both reducing proliferation and enhancing apoptosis of tumor cells. The gene discussed is MAP2K7; the disease is neoplasm.